EASTWOOD BIO-MEDICAL CANADA INC.
#1130 - 4871 Shell Road
Richmond, British Columbia
V6X 3Z6
TSX-V: EBM
NEWS RELEASE
Eastwood Bio-Medical Canada Inc. Begins Commercial Production of Natural Statin Product
December 18, 2018 – Richmond, British Columbia – Eastwood Bio-Medical Canada Inc. (TSX-V: EBM) (the “Company”) is pleased to announce that the Company has begun commercial production of a natural statin products. Statins, or HMG CoA reductase inhibitors, are the main active components of the most popular and effective products on the market for cholesterol control. Over the years, pharmaceutical companies have used statins in some of their best-selling drugs that prevent cardiovascular diseases such as heart attacks and strokes.
The Company’s new product, Eleotin R-Square C1 Formula is made entirely of natural ingredients such as red yeast rice, known to have the same cholesterol-lowering effects but with fewer potential side effects. Published studies have also shown the possibilities of other health benefits such as boosting immune systems and anti-hypertension effects.
Yunji Kim, President and CEO, commented, “We have been aggressively researching and developing natural sourced solutions for some of the biggest health problems out there. With our state of the art facilities ready and capable of producing these solutions on a mass scale, I believe we are ready to serve our fast growing clientele.”
About Eastwood Bio-Medical Canada, Inc.:
The Company is a Vancouver based company whose Eleotin brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.
Eleotin was initially developed by the scientists at the Julia McFarlane Diabetes Research Center (JMDRC) at the University of Calgary in Alberta, Canada. The JMDRC is a leader in research on Type I and Type II diabetes. After the initial development by the JMDRC, research and development were continued by Eastwood Bio-Medical Research Inc., the Company, and other institutions around the world, including Tsinghua University of the People’s Republic of China. Eleotin products have been endorsed by thousands of doctors and medical associations around the globe, and authorized by Advertising Standards Canada (ASC) to be marketed as the
‘World’s #1 Doctor Recommended Natural Source Healthy Blood Glucose Promoting Product
available in Canada.’
More information on Eastwood Bio-Medical Canada Inc., can be found on the website www.eleotin.ca.
For further information, please contact:
Eastwood Bio-Medical Canada Inc.
Yunji Kim, President and Chief Executive Officer
Telephone: (604) 247-2100
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. There is no assurance that the new products will produce the revenue increase the Company expects. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
